Patients with gliomas harboring IDH mutations typically present at a younger age compared to IDH wild type gliomas, with a peak incidence between ages of 35 and 44, according to the Central Brain Tumor Registry of the United States (CBTRUS) data base report. This evidence concerns the gene IDH2 and central nervous system cancer.